Oncoustics Closes New Funding To Advance Its Ai Innovations In Ultrasound And Address Huge Unmet Clinical Needs In Liver Disease
Oncoustics Closes New Funding To Advance Its Ai Innovations In Ultrasound And Address Huge Unmet Clinical Needs In Liver Disease
07/21/22, 11:05 AM
Location
torontoIndustry
science and engineering
data and analytics
health care
TORONTO, ON and SAN FRANCISCO, CA / July 21, 2022 / Oncoustics (http://www.oncoustics.com), the leader in ultrasound-based tissue characterization solutions announces the initial close of a $5 million+ seed round of funding to advance its SaMD (software as a medical device) technology for the low-cost assessment of structural diseases at point of care. Oncoustics' first products will focus on liver disease, one of the fastest-growing causes of morbidity and mortality in the world. The round is co-led by Creative Ventures and Saltagen Ventures.
Company Info
Location
toronto, ontario, canada
Additional Info
Oncoustics (www.oncoustics.com) applies AI to raw ultrasound signals to do tissue characterization at point of care for low-cost, noninvasive surveillance, diagnostics, and treatment monitoring of diseases with high unmet clinical need. The Oncoustics solutions for ultrasound will be submitted for regulatory approval in the United States (FDA 510(k)), Canada (Health Canada medical device license) and the European Union (CE Mark). The OnX Liver Assessment Solution has not been cleared for clinical use and is For Investigational Use Only.
For further information, visit www.oncoustics.com.